Who is sponsoring NCT05411497?

NCT05411497 is sponsored by Mayo Clinic.

What drugs are being tested in NCT05411497?

Interventions in NCT05411497: Autologous MUC1-activated T-cells, Cyclophosphamide.

What condition does NCT05411497 study?

NCT05411497 studies Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma.

Is NCT05411497 still recruiting?

NCT05411497 is currently active, enrolled. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT05411497

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Active, enrolled Phase 1 Last updated 3 April 2026

What this trial tests

Phase 1 trial testing Autologous MUC1-activated T-cells in Recurrent Plasma Cell Myeloma in 5 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

20 June 2022

Primary endpoint
18 August 2027

18 August 2027

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	20 June 2022
Primary completion	18 August 2027
Estimated completion	18 August 2027
Sites	2 locations across United States

Drugs / interventions tested

Autologous MUC1-activated T-cells — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Recurrent Plasma Cell Myeloma — all drugs for Recurrent Plasma Cell Myeloma →
Refractory Plasma Cell Myeloma — all drugs for Refractory Plasma Cell Myeloma →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Recurrent Plasma Cell Myeloma or Refractory Plasma Cell Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial tests the safety, side effects and best dose of MUC1-activated T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory) and is positive for expression of the MUC1 protein. T-cells are infection fighting blood cells that can kill cancer cells. MUC1-activated T-cells are made from the body's own T cells. The manufactured T-cells are made to target the MUC1 genetic marker and may help the body's immune system identify and kill cancer cells.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The network map of mucin 1 mediated signaling in cancer progression and immune modulation.
Palollathil A, Dagamajalu S, Ahmed M, Vijayakumar M, et al · · 2025 · cited 4× · PMID 40711726 · DOI 10.1007/s12672-025-03030-z
Application of dendritic cell extracellular vesicles as a valid nanoparticle platform for cancer therapies: a narrative review.
Nezamdoust FV, Nezhad-Mokhtari P, Mirzaahmadi B, Mazloumi Z, et al · · 2026 · PMID 42010708 · DOI 10.1186/s13287-026-05011-7

Verify or expand the search:

Other trials of Autologous MUC1-activated T-cells

Trials testing the same drug.

NCT06483048 — MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer · Phase 1 · recruiting

Other recruiting trials for Recurrent Plasma Cell Myeloma

Currently open trials in the same condition.

NCT04756401 — Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple M · Phase 2 · active not recruiting
NCT05363111 — Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma · Phase 1 · recruiting
NCT05391750 — Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma · Phase 1 · active not recruiting
NCT05514990 — Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AM · Phase 1, PHASE2 · active not recruiting
NCT05312255 — Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple · NA · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05411497 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05411497.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing